AZD7442 reduced risk of developing severe COVID - 19 or death in TACKLE Phase III outpatient treatment trial

A combination of an antibody given to patients with mild-to-moderate symptoms of Covid-19 has been successful in a trial in the US, according to the British Medical Journal (BMJ) and the Royal Society of Pharmaceuticals (RCN).

Source: mynewsdesk.com
Published on 2021-10-11